teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection
64007957MMY1003
Phase 2 small_molecule active
Quick answer
teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection for Multiple Myeloma is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active